Related Experiment Videos
MR-14134, a new benzothiazepine with central hypotensive action
P Prieto1, R Carrón, M J Montero
1Department of Physiology and Pharmacology, Faculty of Pharmacy, University of Salamanca, Spain.
Pharmacology
|August 1, 1995
Summary
MR-14134, a novel benzothiazepine, effectively lowers blood pressure and heart rate in rats, with effects mediated by the central nervous system via alpha 2B-adrenoceptors and I1 imidazoline receptors.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Neuroscience
Background:
- Benzothiazepine derivatives are explored for cardiovascular effects.
- Diltiazem is a known calcium channel blocker with cardiovascular applications.
- Understanding novel compound mechanisms is crucial for drug development.
Purpose of the Study:
- To compare the cardiovascular effects of MR-14134 and diltiazem.
- To investigate the central nervous system involvement of MR-14134.
- To elucidate the receptor targets of MR-14134.
Main Methods:
- Intravenous and intracerebroventricular administration of MR-14134 and diltiazem in anesthetized and pithed rats.
- Assessment of blood pressure and heart rate.
- [3H]clonidine binding assays in rat cerebral cortex.
- Pharmacological antagonism studies.
Main Results:
- MR-14134 induced dose-dependent hypotension and bradycardia, longer-lasting than diltiazem.
- Central administration of MR-14134 reduced blood pressure and heart rate.
- Effects were antagonized by yohimbine and prazosin, indicating alpha-adrenergic and imidazoline receptor involvement.
- MR-14134 and diltiazem showed no affinity for alpha 2A-adrenoceptors.
Conclusions:
- MR-14134 exhibits significant hypotensive and bradycardic effects.
- Unlike diltiazem, MR-14134's actions involve the central nervous system.
- The effects are mediated by alpha 2B-adrenoceptors and I1 imidazoline receptors.